Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jarrod Betz"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 3 (2017)
Externí odkaz:
https://doaj.org/article/cea632b55dc84f95ae5d57656e20abac
Publikováno v:
HeartRhythm Case Reports
Sarcoidosis is an autoimmune disorder in which granulomatous inflammation leads to multiorgan dysfunction. Cardiac involvement in particular is associated with substantial morbidity and mortality.1 Potential cardiac manifestations include atrioventri
Publikováno v:
Current treatment options in cardiovascular medicine. 21(12)
Functional mitral regurgitation (MR) in setting of cardiomyopathy causes significant morbidity and worsened survival. Surgical therapies have failed to demonstrate significant overall benefit for functional MR. More recently, major trials utilizing t
Autor:
Jehu Mathew, Yongfei Wang, Pamela N. Peterson, Jarrod Betz, Sana M. Al-Khatib, Carolina Malta Hansen, David F. Katz, Frederick A. Masoudi, David D. McManus, Ryan T. Borne
Publikováno v:
Journal of the American College of Cardiology. 69:265-274
Background Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago and enrolled few older patients. Objectives This study assessed morbidity and mortality
Autor:
Carolina Malta Hansen, Ryan T. Borne, Pamela N. Peterson, Paul D. Varosy, Mintu P. Turakhia, Yongfei Wang, Jarrod Betz, Sana M. Al-Khatib, Kurt S. Hoffmayer, Ryan T Kipp, Jonathan C. Hsu, Frederick A. Masoudi, David F. Katz
Publikováno v:
JACC: Clinical Electrophysiology. 3:20-28
Objectives This study sought to define the characteristics and risks of death of patients receiving a physician-designated secondary prevention implantable cardioverter-defibrillator (ICD) in contemporary clinical practice. Background Data on utiliza
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
First used in humans in 1980, the implantable cardioverter defibrillator (ICD) was designed to recognize and treat malignant ventricular arrhythmias and thus prevent arrhythmic death.[1][1] Among patients with an aborted episode of sudden cardiac arr
Autor:
David F, Katz, Pamela, Peterson, Ryan T, Borne, Jarrod, Betz, Sana M, Al-Khatib, Paul D, Varosy, Yongfei, Wang, Jonathan C, Hsu, Kurt S, Hoffmayer, Ryan T, Kipp, Carolina Malta, Hansen, Mintu P, Turakhia, Frederick A, Masoudi
Publikováno v:
JACC. Clinical electrophysiology. 3(1)
This study sought to define the characteristics and risks of death of patients receiving a physician-designated secondary prevention implantable cardioverter-defibrillator (ICD) in contemporary clinical practice.Data on utilization and outcomes of IC
Publikováno v:
Current Treatment Options in Cardiovascular Medicine; Dec2019, Vol. 21 Issue 12, p1-8, 8p
Publikováno v:
Globe; 10/23/2023, Vol. 69 Issue 43, p11-11, 7/9p, 2 Color Photographs
Publikováno v:
Journal of the American Heart Association; 2017, Vol. 6 Issue 3, p1-N.PAG, 10p, 3 Charts